Loading stock data…
LCTX
$1.53+0.02 (+1.32%)
Market ClosedLast close May 1
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lineage Cell Therapeutics, Inc. in the Healthcare sector is trading at $1.53. The stock is currently 27% below its 52-week high of $2.09, remaining 1.9% below its 200-day moving average. Technical signals show neutral RSI of 52 and bearish MACD signal, explaining why LCTX maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 52) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.53
Potential Upside
5%
Whystock Fair Value$1.61
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment e...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$406.01M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.80
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-142.61%
Volume
Today's trading volume
1.36M
Recent News
Niagen Bioscience And 2 Additional Promising Penny Stocks For Your Consideration
Over the last 7 days, the United States market has risen by 4.4%, and in the past year, it has climbed an impressive 32%, with earnings expected to grow by 16% annually. While penny stocks might seem like a relic from earlier market times, they continue to represent smaller or less-established companies that can offer significant value when chosen wisely. By focusing on those with strong financials and clear growth potential, investors can uncover opportunities in these niche stocks that may...
Lineage Cell (LCTX) Launches Its Latest Cell Therapy Program
Lineage Cell Therapeutics Inc. (NYSE:LCTX) is one of the 10 best penny stocks that could triple your money. On March 24, Lineage Cell Therapeutics Inc. (NYSE:LCTX) announced the launch of COR1, a new preclinical cell therapy program targeting corneal endothelial disease. The company is leveraging its proprietary AlloSCOPE platform to develop scalable off-the-shelf cell therapies […]
Lineage Cell Therapeutics, Inc. Q4 2025 Earnings Call Summary
Moby summary of Lineage Cell Therapeutics, Inc.'s Q4 2025 earnings call
Lineage Cell Therapeutics Q4 Earnings Call Highlights
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) used its quarterly conference call to highlight a longer cash runway following recent warrant exercises, progress in manufacturing capabilities, and early internal validation work in a newly launched islet cell research initiative. Management also review
Lineage Cell (LCTX) Reports Break-Even Earnings for Q4
Lineage Cell (LCTX) delivered earnings and revenue surprises of +100.00% and +187.81%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?